PRIMO 2023 | Do ICIs with PARP inhibitors have a role in treating ovarian cancer?

Alexander Olawaiye, MD, FRCOG, FACOG, FACS, University of Pittsburgh, Pittsburgh, PA, comments on the efficacy of combining checkpoint inhibitors (ICIs) with PARP inhibitors. Whilst ICIs alone have proven to be ineffective against ovarian cancer, combining them with other therapies such as PARP inhibitors may have a synergistic effect. However, trials assessing this combination have produced mixed results. This interview took place at the Practical Recommendations in Immuno and Molecular Oncology (PRIMO) 2023 Congress in Honolulu, HI.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.